Advertisement

Uroonkologie pp 189-201 | Cite as

Grundlagen der Palliativmedizin

  • Marianne Kloke
  • Jörg Hense
  • Michael Stahl

Zusammenfassung

Die Weltgesundheitsorganisation (WHO) definierte 1990 Palliativmedizin (PM) als die »umfassende und aktive Behandlung von Patienten, deren Erkrankung einer kurativen Therapie nicht mehr zugänglich ist und für die das Behandlungsziel die bestmögliche Lebensqualität für sie selbst und ihre Angehörigen ist« und räumte ihr höchste Priorität ein. Dies konnte auch auf dem Hintergrund erheblicher Fortschritte auf dem Gebiet der Schmerztherapie (u. a. durch Einführung der oralen retardierten Opioide) und einer stetigen Weiterentwicklung evidenzbasierter Strategien zur Symptomkontrolle (z. B. Konzepte bei terminal deliranten Zuständen, nicht operablen intestinalen Obstruktionen, Atemnotsyndromen etc.) geschehen.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

Literatur zu Kap. 12.1–12.2

  1. Arzneimittelkommission der Deutschen Ärzteschaft (2000) Empfehlungen zur TumorschmerztherapieGoogle Scholar
  2. Ballantyne J (2003) Chronic pain following treatment for cancer: the role of opioids. Oncologis 8.6: 567–575CrossRefGoogle Scholar
  3. Bruera E, Schoeller T, Wenk R et al. (1995) A prospective multicenter assessment of the Edmonton staging system for cancer pain. J Pain Symptom Manag 10.5: 348–355CrossRefGoogle Scholar
  4. Bruera E, Pereira J, Watanabe S et al. (1996) Opioid rotation in patients with cancer pain. A retrospective comparison of dose ratios between methadone, hydromorphone and morphine. Cancer 78: 852–857CrossRefPubMedGoogle Scholar
  5. Caraceni A, Portenoy RK, and a working group of the IASP force on cancer pain (1999) An international survey of cancer patients characteristic and syndromes. Pain 82: 263–274CrossRefPubMedGoogle Scholar
  6. Davis MP, Walsh D (2001) Methadone for relief of cancer pain: a review of pharmacokinetics, pharmacodynamics, drug interactions and protocols of administration. Support Care Cancer 9: 73–83CrossRefPubMedGoogle Scholar
  7. Deutsche Interdisziplinäre Vereinigung zur Schmerztherapie (DIVS) (1999) Leitlinien zur Tumorschmerztherapie. Tumordiag Ther 20: 105–129Google Scholar
  8. Expert Working Group of EAPC (1996) Morphine in cancer pain: modes of administration. Br Med J 312: 823–826Google Scholar
  9. Expert Working Group of EAPC (2001) Morphine and alternative opioids in cancer pain: the EAPC recommandation. Br J Cancer 84: 587–593CrossRefGoogle Scholar
  10. Fainsinger RL, Nekolaichuk C (2008) A “TNM” classification system for cancer pain: the Edmonton Classification System for Cancer Pain (ECS-CP). Support Care Cancer 2008 16(6): 547–55CrossRefPubMedGoogle Scholar
  11. Foley KM (2003) Opioids and chronic neuropathic pain. N Engl J Med 348: 1279–1281CrossRefPubMedGoogle Scholar
  12. Grond S, Zech D, Schug SA et al (1991) Validation of the World Health Organisation guidelines for cancer pain relief during the last days and hours of life. J Pain Sympt Manag 6/7: 411–412CrossRefGoogle Scholar
  13. He L, Fong J, von Zastrow M, Whistler JL (2002) Regulation of opioid receptor trafficking and morphine tolerance by receptor oligomerisation. Cell 25.108: 271–282CrossRefGoogle Scholar
  14. Indelicato RA, Portenoy RK (2002) Opioid rotation in the management of refractory cancer pain. J Clin Oncol 20: 348–352PubMedGoogle Scholar
  15. Itoh A, Noda Y, Mamiya T, Hasega T, Nabeshima T (1998) A therapeutic strategy to prevent morphine dependence and tolerence by coadministration of cAMP-related reagents with morphine. Meth Find Exp Clin Pharmacol 20.7: 619–625CrossRefGoogle Scholar
  16. Lotsch J, Starke C, Grosch S et al. (2002) The polymorphism A118G of the human mu-opioid receptor gene decreases the pupil constrictory effect of morphine-6-glucuronide but not that of morphine. Pharmacogenetics 12.1: 3–9CrossRefPubMedGoogle Scholar
  17. Lotsch J, Zimmermann M, Darimont J et al (2002) Does the A118G polymoprhism at the mu-opioid receptor gene protect against moprhin-6-glucuronide toxicity? Anesthesiology 97.4: 814–819CrossRefPubMedGoogle Scholar
  18. Mao J, Backil S, RuRong J Grewo L (2002) Chronic morphine induces downregulation of spinal glutamate transporters: implications in morphine tolerance and abnormal pain sensation. J Neurosci 18: 8312–8323Google Scholar
  19. Menten J (2004) Opioid tolerance in advanced cancer patients: a self-limiting phenomen. Palliat Med 18.4: 310Google Scholar
  20. Pasternak GW (2003) Insights into the genetics of mu-opioid analgesics: lessons from the clinic. Eur J Palliat Care 10.2 (Suppl) 37–38Google Scholar
  21. Raith K, Hochhaus G (2003) Drugs used in the treatment of opioid tolerance and physical dependence: a review. Bull Cancer 90 (8–9) 795–806Google Scholar
  22. Thompson CM, Wojno H, Greiner E et al (2002) Activation of G-proteins by morphine and codeine congeners: insights to the relevance of O-and N-demethylated metabolites at mu-and delta-opioid receptors. J Pharmacol Exp Ther 308.2: 547–554CrossRefGoogle Scholar
  23. Ueda H, Inoue M. Mizuno K (2003) New approaches to study the development of morphine tolerance and dependence. Life Sci 72: 313–320CrossRefGoogle Scholar
  24. Radbruch L, Loick G et al (2000) MIDOS. Elektronische Datenbank für Palliativstationen. Schmerz 214: 231–239CrossRefGoogle Scholar
  25. Rowbotham MC, Twillin L, Davies PS et al. (2003) Oral opioid therapy for chronic peripheral and central neuropathic pain. N Engl J Med 348: 1223–1232CrossRefPubMedGoogle Scholar
  26. Tegeder I, Lotsch J, Geisslinger G (1999) Pharmacokinetics in liver disease. Clin Pharmacokinet 37.1: 17–40CrossRefPubMedGoogle Scholar
  27. Ventafridda V, Tamburini M, Caraceni A (1987) A validation study of the WHO method for cancer pain relief. Cancer 59: 850–856CrossRefPubMedGoogle Scholar
  28. World Health Organisation. Cancer pain relief. 2nd edn. 1996. WHO, GenevaGoogle Scholar
  29. Zykicz Z: Opioids: are there any differences between them? Eur J Palliat Care 2003 Abstracts of the 8th Congress of the EAPC, p 57Google Scholar

Literatur zu Kap. 12.3

  1. Bennett M, Cresswell H (2003) Factors influencing. constipation in advanced cancer patients: a prospective study of opioid dose, dantron dose and physical functioning. Palliat Med 17 (5) 418–22CrossRefPubMedGoogle Scholar
  2. Bruera E, Moyano JR, Sala R, Rico MA, Bosnjak S, Bertolino M, Willey J, Strasser F, Palmer JL (2004) Dexamethasone in addition to metoclopramide for chronic nausea in patients with advanced cancer: a randomized controlled trial. J Pain Symptom Manage 28 (4) 381–388CrossRefPubMedGoogle Scholar
  3. Davis MP, Walsh D (2000) Treatment of nausea and vomiting in advanced cancer. Support Care Cancer 8 (6): 444–452CrossRefPubMedGoogle Scholar
  4. Fine PG (2002) Analgesia issues in palliative care: bone pain, controlled release opioids, managing opioid-induced constipation and nifedipine as an analgesic. J Pain Palliat Care Pharmacother. 16 (1): 93–97 ReviewPubMedGoogle Scholar
  5. Glare P, Pereira G, Kristjanson LJ, Stockler M, Tattersall M (2004) Systematic review of the efficacy of antiemetics in the treatment of nausea in patients with far-advanced cancer Support Care Cancer 12 (6): 432–40Google Scholar
  6. Muir JC, von Gunten CF (2001) Abdominal cancer, nausea, and vomiting J Palliat Med Fall 4 (3): 391–394Google Scholar
  7. Tamayo AC, Diaz-Zuluaga PA (2004) Management of opioid-induced bowel dysfunction in cancer patients. Support Care Cancer 12 (9): 613–618PubMedGoogle Scholar
  8. Schwarzer A, Nauck F, Klaschik E (2003/2004) Strong opioids and constipation Schmerz 2004 Mar 5; Palliat Med 17 (5): 418–422Google Scholar

Literatur zu Kap. 12.4

  1. Ripamonti C, Fusco F (2002) Respiratory problems in advanced cancer, Support Care Cancer 10 (3) 204–216CrossRefPubMedGoogle Scholar
  2. LeGrand SB, Khawam EA, Walsh D, Rivera NI (2003) Opioids, respiratory function, and dyspnea. Am J Hosp Palliat Care 20 (1) 57–61CrossRefPubMedGoogle Scholar
  3. Dudgeon DJ. (2002) Managing dyspnea and cough. Hematol Oncol Clin North Am 16 (3) 557–77, viiiCrossRefPubMedGoogle Scholar
  4. Booth S, Anderson H et al (2004) the use of oxygen in the palliation of breathlessness. A report of the expert working group of the scientific committee of the association of palliative care. Resp Med 98: 66–77CrossRefGoogle Scholar

Literatur zu Kap. 12.5

  1. Braun TC, Hagen NA, Clark T (2003) Development of a clinical practice guideline for palliative sedation. J Palliat Med 6: 345–427CrossRefPubMedGoogle Scholar
  2. Chater S, Viola R, Paterson J, Jarvis (1998) Sedation for intractable distress in the dying — a survey of experts. Palliat Med 12: 255–269CrossRefPubMedGoogle Scholar
  3. Cherny NI, Portenoy RK (1994) Sedation in the management of refractory symptoms: Guidelines for evaluation and treatment. J Palliat Care 10: 31–38PubMedGoogle Scholar
  4. Materstvedt LJ, Clark D, Ellershaw J, Forde R, Gravgaard AM, Muller-Busch HC, Porta i Sales J, Rapin CH. (2004) Euthanasie und ärztlich unterstützter Suizid: eine Stellungnahme der Ethics Task Force der European Association for Palliat Care. Z Palliativmed 5: 102–106CrossRefGoogle Scholar
  5. Müller-Busch HC (2004) Sterbende sedieren? DMW 129: 701–704Google Scholar

Copyright information

© Springer Medizin Verlag Heidelberg 2009

Authors and Affiliations

  • Marianne Kloke
    • 1
  • Jörg Hense
    • 2
  • Michael Stahl
    • 1
  1. 1.Klinik für Innere Medizin IV, Internistische Onkologie/HämatologieKliniken Essen-Mitte HuyssensstiftEssen
  2. 2.Innere Klinik und Poliklinik (Tumorforschung)Universitätsklinikum EssenEssen

Personalised recommendations